Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cedres Perez, S. [1 ]
Prat, A. [1 ]
Felip, E. [1 ]
Peralta, S. [1 ]
Perez, J. [1 ]
del Campo, J. [1 ]
Sala, G. [1 ]
Andreu, J. [1 ]
Pallisa, E. [1 ]
Baselga, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19125
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [2] Skin rash as surrogate marker of efficacy in patients with non-small cell lung cancer treated with erlotinib
    Cobo, M.
    Cardenal, F.
    Insa, A.
    Domine, M.
    Lianes, P.
    Guillot, M.
    Montesinos, J.
    Bover, I.
    Amador, M. L.
    Paz-Ares, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Cutaneous toxicity in erlotinib treatment for advanced non-small cell lung cancer (NSCLC)
    Bernabee, R.
    Cobo, M.
    Barneto, I.
    Valdivia, J.
    Fernandez, I.
    Rueda, A.
    Villatoro, R.
    de la Curz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer
    Karaca, Halit
    Geredeli, Caglayan
    Kaplan, M. Ali
    Demirci, Umut
    Alici, Suleyman
    Artac, Mehmet
    Isikdogan, Abdurrahman
    Benekli, Mustafa
    Balakan, Ozan
    Arpaci, Erkan
    Budakoglu, Burcin
    Uncu, Dogan
    Guler, Tunc
    Berk, Veil
    Ozkan, Metin
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (01): : 1 - 6
  • [5] Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
    Hotta, Katsuyuki
    Fujiwara, Yoshiro
    Matsuo, Keitaro
    Kiura, Kutsuyuki
    Takigawa, Nagio
    Tabata, Masahira
    Tanimoto, Mitsune
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 311 - 317
  • [6] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [7] Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer
    Zhou, Songwen
    Ren, Shengxiang
    Yan, Lianghua
    Zhang, Ling
    Tang, Liang
    Zhang, Jie
    Zhou, Caicun
    RESPIROLOGY, 2009, 14 (05) : 709 - 715
  • [8] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [9] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    Carbone, David P.
    Salmon, J. Stuart
    Billheimer, Dean
    Chen, Heidi
    Sandler, Alan
    Roder, Heinrich
    Roder, Joanna
    Tsypin, Maxim
    Herbst, Roy S.
    Tsao, Anne S.
    Tran, Hai T.
    Dang, Thao P.
    LUNG CANCER, 2010, 69 (03) : 337 - 340
12345